These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1565448)

  • 1. Correlation of serum immunoglobulin E elevations with clinical stages of dysthyroid orbitopathy.
    Raikow RB; Tyutyunikov A; Kennerdell JS; Kazim M; Dalbow MH; Scalise D
    Ophthalmology; 1992 Mar; 99(3):361-5. PubMed ID: 1565448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Orbital-bony decompression in patients with dysthyroid orbitopathy--first Croatian experiences].
    Juri J; Stiglmayer N; Kuzman T
    Acta Med Croatica; 2006; 60(2):83-6. PubMed ID: 16848193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed orbital infection after endoscopic orbital decompression for dysthyroid orbitopathy.
    Remulla HD; Gliklich RE; Metson R; Rubin PA
    Ophthalmology; 2000 May; 107(5):947-50. PubMed ID: 10811088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Endoscopic transnasal orbital decompression for dysthyroid orbitopathy].
    Zhang L; Jiang R; Men X; Liu G; Zhong H; Sun T
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2002 Dec; 37(6):447-9. PubMed ID: 12966807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical evidence for IgE involvement in Graves' orbitopathy.
    Raikow RB; Dalbow MH; Kennerdell JS; Compher K; Machen L; Hiller W; Blendermann D
    Ophthalmology; 1990 May; 97(5):629-35. PubMed ID: 2188194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum anti-Staphylococcus pseudintermedius IgE and IgG antibodies in dogs with atopic dermatitis and nonatopic dogs.
    Bexley J; Nuttall TJ; Hammerberg B; Fitzgerald JR; Halliwell RE
    Vet Dermatol; 2013 Feb; 24(1):19-24.e5-6. PubMed ID: 23331675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detectable serum IgE levels in Graves' ophthalmopathy.
    Molnár I; Horváth S; Balázs C
    Eur J Med Res; 1996 Sep; 1(11):543-6. PubMed ID: 9438158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-examination of peripheral blood T cell subsets in dysthyroid orbitopathy.
    Tyutyunikov A; Raikow RB; Kennerdell JS; Kazim M; Dalbow MH; Scalise D
    Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2299-303. PubMed ID: 1351477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of upper eyelid retraction associated with dysthyroid orbitopathy during the acute inflammatory phase with botulinum toxin type A].
    Nava Castañeda A; Tovilla Canales JL; Garnica Hayashi L; Velasco Y Levy A
    J Fr Ophtalmol; 2017 Apr; 40(4):279-284. PubMed ID: 28336282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease.
    Sato A; Takemura Y; Yamada T; Ohtsuka H; Sakai H; Miyahara Y; Aizawa T; Terao A; Onuma S; Junen K; Kanamori A; Nakamura Y; Tejima E; Ito Y; Kamijo K
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3602-5. PubMed ID: 10523002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular neuromyotonia in Graves dysthyroid orbitopathy.
    Chung SM; Lee AG; Holds JB; Roper-Hall G; Cruz OA
    Arch Ophthalmol; 1997 Mar; 115(3):365-70. PubMed ID: 9076209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis of nasal polyposis by immunoglobulin E and interleukin-5 is completed by transforming growth factor-beta1.
    Hirschberg A; Jókúti A; Darvas Z; Almay K; Répássy G; Falus A
    Laryngoscope; 2003 Jan; 113(1):120-4. PubMed ID: 12514394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment of dysthyroid orbitopathy: a multidisciplinary disease].
    Leray B; Imbert P; Thouvenin D; Boutault F; Caron P
    J Fr Ophtalmol; 2013 Dec; 36(10):874-85. PubMed ID: 24239215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
    Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
    Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The histological substrate of the extraocular muscle thickening seen in dysthyroid orbitopathy (author's transl)].
    Daicker B
    Klin Monbl Augenheilkd; 1979 Jun; 174(6):843-7. PubMed ID: 158105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of soluble E selectin levels in patients with Graves' disease and thyroid orbitopathy].
    Kulig G; Pilarska K; Kulig J; Robaczyk M; Gromniak E
    Przegl Lek; 2004; 61(12):1314-8. PubMed ID: 15850320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of moderate and severe dysthyroid orbitopathy: about 22 cases].
    Daldoul N; Knani L; Gatfaoui F; Mahjoub H
    Pan Afr Med J; 2017; 27():257. PubMed ID: 29187926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.